Transl Clin Pharmacol.
2023 Sep;31(3):125-130. 10.12793/tcp.2023.31.e14.
What goes in the regulatory clinical pharmacology package for an oncolytic virus?
- Affiliations
-
- 1Brain Boutique, Inc., Seoul 06132, Korea
- 2Cha Biotech, Seongnam 13488, Korea
- 3Certara, Paris 75008, France
- KMID: 2552413
- DOI: http://doi.org/10.12793/tcp.2023.31.e14
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Early Experience of Oncolytic Virus Injection Combined with Sorafenib in a Patient with Advanced Hepatocellular Carcinoma and Portal Vein Thrombosis
- Effect of aldosterone on the amplification of oncolytic vaccinia virus in human cancer lines
- Mesenchymal stem cells enable delivery of an oncolytic adenovirus specifically to the tumor without posing any risk associated with systemic administration of naked virions to the host
- Validation of “sasLM,” an R package for linear models with type III sum of squares
- Reoviral Oncotropism Against c-Myc Overexpressing HS 68 Cells
